Immix Biopharma

Immix Biopharma, Inc. (ImmixBio), headquartered in Los Angeles, California, is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies. The company employs 17 individuals and generates $3 million in annual revenue. ImmixBio is publicly traded on the Nasdaq under the ticker symbol IMMX. ImmixBio specializes in developing next-generation cell therapies for the treatment of AL Amyloidosis and other autoimmune diseases. Their lead cell therapy, NXC-201, is an FDA IND-cleared CAR-T therapy currently being evaluated in the Phase 1b/2 NEXICART-1 clinical trial. NXC-201 has demonstrated the potential to be the world's first "Single-Day CRS" CAR-T, offering a faster recovery time for patients. ImmixBio's NXC-201 has been recognized for its potential by receiving Orphan Drug Designation (ODD) by both the FDA in both AL Amyloidosis and multiple myeloma, and by the European Commission (EMA) in AL Amyloidosis. This designation underscores the significant unmet medical need addressed by ImmixBio's groundbreaking research. For more information about Immix Biopharma and its innovative cell therapies, please visit www.immixbio.com and www.BeProactiveInAL.com.